78712-62-6

Usage

Uses

Used in Pharmaceutical Industry:
Hexanoic acid, 6-bromo-2,2-dimethyl-, ethyl ester is used as a chemical intermediate for the synthesis of pharmaceuticals. It plays a crucial role in the development of new drugs and medicines.
Used in Agrochemical Industry:
In the agrochemical industry, Hexanoic acid, 6-bromo-2,2-dimethyl-, ethyl ester is used as a precursor in the production of various agrochemicals. It helps in the development of effective and safe products for agricultural applications.
Used in Flavor and Fragrance Industry:
Hexanoic acid, 6-bromo-2,2-dimethyl-, ethyl ester is used as a flavoring agent due to its fruity odor. It is incorporated into various food and beverage products to enhance their taste and aroma.
Used as a Solvent:
This chemical compound is also used as a solvent in various chemical processes. Its properties make it suitable for dissolving and mixing with other substances, facilitating reactions and processes.
Used in Chemical Production:
Ethyl 6-bromo-2,2-dimethylhexanoate serves as an intermediate in the production of other chemicals. It is a key component in the synthesis of various compounds used in different industries.
Safety Precautions:

Upstream product

• 110-52-1 1,4-dibromo-butane 
• 97-62-1 Ethyl isobutyrate 
• 144-55-8 sodium hydrogencarbonate 

Downstream Products

• 91304-05-1 ethyl 2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)methoxy]methyl]ethoxy]hexanoate 
• 91304-04-0 2,2-dimethyl-6-[2-(1H-imidazol-1-yl)-1-[[(4-methoxyphenyl)methoxy]methyl]ethoxy]hexanoic acid 
• 109837-89-0 6-[(S)-2-Imidazol-1-yl-1-(4-methoxy-benzyloxymethyl)-ethoxy]-2,2-dimethyl-hexanoic acid 
• 109837-88-9 6-[(R)-2-Imidazol-1-yl-1-(4-methoxy-benzyloxymethyl)-ethoxy]-2,2-dimethyl-hexanoic acid 
• 738606-47-8 7-isocyano-2,2-dimethyl-7-(tolyl-4-sulfonyl)heptanoic acid ethyl ester 
• 413626-91-2 7-Isocyano-2,2,12,12,-tetramethyl-7-(toluene-4-sulfonyl)-tridecanedioic acid diethyl ester 
• 769174-64-3 2-[7-isocyano-2,2-dimethyl-7-(tolyl-4-sulfonyl)heptyloxy]tetrahydropyran 
• 769174-66-5 C₃₄H₅₅NO₆S 
• 413626-89-8 2-[7-isocyano-2,2,12,12-tetramethyl-13-(tetrahydro-pyran-2-yloxy)-7-(toluene-4-sulfonyl)-tridecyloxy]-tetrahydro-pyran 
• 769174-70-1 C₃₆H₅₉NO₆S 
• 769174-68-7 C₄₀H₅₉NO₆S 
• 1373492-24-0 (5-ethoxycarbonyl-5-methylhexyl)-triphenylphosphonium bromide 
• 1373492-27-3 7-bromo-7-(2-chlorophenyl)-2,2-dimethylheptanoic acid ethyl ester 
• 1373491-74-7 7-(2-chlorophenyl)-7-(6,7-dihydro-4H-thieno[3,2-c]pyridin-5-yl)-2,2-dimethylheptanoic acid ethyl ester 

Relevant academic research and scientific papers

Compound and method for synthesizing 8-hydroxy-2,2,14,14-tetramethyl pentadecanedioic acid by adopting compound

The invention belongs to the field of chemical synthesis, and relates to a compound with a structural formula as described in the specification. In the structural formula, R1, R2 and R3 are independently selected from C1-C6 alkyl groups, alkenyl groups and cycloalkyl groups respectively. The invention also provides a method for synthesizing 8-hydroxy-2,2,14,14-tetramethyl pentadecanedioic acid byusing the compound. The method has the advantages of short reaction steps, simplified operation and greatly reduced production cost; and the use of raw materials with high toxicity and danger is avoided, so the method is safer.

Selective PPARδ Modulators Improve Mitochondrial Function: Potential Treatment for Duchenne Muscular Dystrophy (DMD)

The X-ray structure of the previously reported PPARδ modulator 1 bound to the ligand binding domain (LBD) revealed that the amide moiety in 1 exists in the thermodynamically disfavored cis-amide orientation. Isosteric replacement of the cis-amide with five-membered heterocycles led to the identification of imidazole 17 (MA-0204), a potent, selective PPARδ modulator with good pharmacokinetic properties. MA-0204 was tested in vivo in mice and in vitro in patient-derived muscle myoblasts (from Duchenne Muscular Dystrophy (DMD) patients); 17 altered the expression of PPARδ target genes and improved fatty acid oxidation, which supports the therapeutic hypothesis for the study of MA-0204 in DMD patients.

PROCESSES AND INTERMEDIATES FOR PREPARING α,ω-DICARBOXYLIC ACID-TERMINATED DIALKANE ETHERS

The present disclosure provides a process for the preparation of compounds of formula (III), compounds of formula (V), and corresponding salts of formula (IV). The compounds made by the methods and processes of the invention are particularly useful for ad

PPAR AGONISTS, COMPOUNDS, PHARMACEUTICAL COMPOSITIONS, AND METHODS OF USE THEREOF

Provided herein are compounds of formula (I) useful for the treatment of PPAR-delta related diseases (e.g. mitochondrial diseases, muscular diseases, vascular diseases, demyelinating diseases and metabolic diseases).

ETHER COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

KETONE COMPOUNDS AND COMPOSITIONS FOR CHOLESTEROL MANAGEMENT AND RELATED USES

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Ether compounds and compositions for cholesterol management and related uses

The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Ketone compounds and compositions for cholesterol management and related uses

The present invention relates to novel ketone compounds, compositions comprising ketone compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising a ketone compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.

Methods for synthesizing ether compounds and intermediates therefor

The present invention relates to novel ether compounds, compositions comprising ether compounds, and methods useful for treating and preventing cardiovascular diseases, dyslipidemias, dysproteinemias, and glucose metabolism disorders comprising administering a composition comprising an ether compound. The compounds, compositions, and methods of the invention are also useful for treating and preventing Alzheimer's Disease, Syndrome X, peroxisome proliferator activated receptor-related disorders, septicemia, thrombotic disorders, obesity, pancreatitis, hypertension, renal disease, cancer, inflammation, and impotence. In certain embodiments, the compounds, compositions, and methods of the invention are useful in combination therapy with other therapeutics, such as hypocholesterolemic and hypoglycemic agents.